Rubulavirus
If not vaccinated against mumps, susceptible individuals catch the disease by breathing around an infected person who has coughed or sneezed, releasing their contaminated saliva. Those who have had mumps are usually immune to future infections of the disease. Children have the highest risk of catching mumps, and it is rare for an adult to contract mumps. The incubation period for mumps can range from a couple weeks to a month, while the illness period is a few weeks. The swelling of the salivary glands is caused when the virus travels from the respiratory tract to the salivary glands and multiplies within the glands, causing the glands to swell.
List of dangerous snakes
It is estimated that only 10 to 15 mg will kill a human adult; however, its bites deliver about 120 mg of venom on average, although they may deliver up to 400 mg of venom in a single bite. If bitten, severe neurotoxicity invariably ensues rapidly. This is because of several factors that include the high potency of their venom, the unusual composition of synergistic toxins contained within the venom which bring on severe symptoms of envenomation and death much faster than any other venomous snake in the world. In addition, the species itself possesses the most advanced, evolved, and efficient venom delivery apparatus among all venomous snakes, and the most advanced and evolved dentition of all elapids. Black mambas possess the longest fangs of any elapid, averaging around , but may grow as long as . Another feature that distinguishes the dentition and venom delivery apparatus of this species from all other elapids, as well as other species of venomous snake including those of the family Viperidae, is the fact that its fangs are positioned well forward at the most-anterior position possible in its mouth - right up in the front of its upper jaw. The proteins in black mamba venom are of low molecular weight, low viscosity, and the venom's high activity in terms of hyaluronidases, which is also essential in facilitating dispersion of venom toxins throughout tissue (spreading the venom through the body) by catalyzing the hydrolysis of hyaluronan, a constituent of the extracellular matrix (ECM), hyaluronidase lowers the viscosity of hyaluronan, and Dendroaspin natriuretic peptide (DNP), a newly discovered component of mamba venom, is the most-potent natriuretic peptide and it's unique to the genus "Dendroaspis", or mambas. It is a polypeptide analogous to the human atrial natriuretic peptide; it is responsible for causing diuresis through natriuresis and dilating the vessel bloodstream, which results in, among other things, acceleration of venom distribution in the body of the victim, thereby increasing tissue permeability. These advanced and highly evolved physical and biological features combined with this species' large size, explosive aggression, and quickness make the black mamba a terrifying adversary. Neurological, respiratory, and cardiovascular symptoms rapidly begin to manifest, usually within less than ten minutes. Common symptoms are rapid onset of dizziness, drowsiness, headache, coughing or difficulty breathing, convulsions, and an erratic heartbeat. Other common symptoms which come on rapidly include neuromuscular symptoms, shock, loss of consciousness, hypotension, pallor, ataxia, excessive salivation (oral secretions may become profuse and thick), limb paralysis, nausea and vomiting, ptosis, fever, and severe abdominal pain. Local tissue damage appears to be relatively infrequent and of minor severity in most cases of black mamba envenomation. Edema is typically minimal. Acute renal failure has been reported in a few cases of black mamba bites in humans as well as in animal models. The venom of this species has been known to cause permanent paralysis in some cases. Death is due to suffocation resulting from paralysis of the respiratory muscles. Untreated black mamba bites have a mortality rate of 100%. Antivenom therapy is the mainstay of treatment for black mamba envenomation. A polyvalent antivenom produced by the South African Institute for Medical Research (SAIMR) is used to treat all black mamba bites from different localities. Because of the availability of antivenom, a bite from a black mamba no longer results in certain death, but in order for the antivenom therapy to be successful, vigorous treatment and large doses of antivenom must be administered rapidly post-envenomation. In case studies of black mamba envenomation, respiratory paralysis has occurred in less than 15 minutes. Envenomation by this species invariably causes severe neurotoxicity because black mambas often strike repeatedly in a single lunge, biting the victim up to 12 times in extremely rapid succession. Such an attack is fast, lasting less than one second, and so it may appear to be a single strike and single bite. With each bite, the snake delivers anywhere from 100 to 400 mg of a rapid-acting and virulently toxic venom. As a result, the doses of antivenom required are often massive (10–30+ vials) for bites from this species. Although antivenom saves many lives, mortality due to black mamba envenomation is still at 14%, even with antivenom treatment. In addition to antivenom treatment, endotracheal intubation and mechanical ventilation are required for supportive therapy.